| 產品名稱 |
NCI-H196 [H196] |
| 商品貨號 |
B165298 |
| Organism |
Homo sapiens, human |
| Tissue |
lung; derived from metastatic site: pleural effusion |
| Product Format |
frozen |
| Culture Properties |
adherent |
| Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease |
stage E,carcinoma; variant small cell lung cancer |
| Age |
68 years |
| Gender |
male |
| Ethnicity |
Caucasian |
| Derivation |
The line was established in October 1979. |
| Clinical Data |
68 years
Caucasian
male
|
| Comments |
The patient received prior chemotherapy and radiation therapy.
The tissue donor was a non-smoker. |
| Complete Growth Medium |
The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing |
Remove medium, and rinse with 0.25% trypsin, 0.03% EDTA solution. Remove the solution and add an additional 1 to 2 mL of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37°C) until the cells detach. Add fresh culture medium, aspirate and dispense into new culture flasks.
Subcultivation Ratio: A subcultivation ratio of 1:4 to 1:6 is recommended
Medium Renewal: Every 2 to 3 days |
| Cryopreservation |
Culture medium, 95%; DMSO, 5% |
| Culture Conditions |
Temperature: 37°C
Atmosphere: 5% CO2 |
| Name of Depositor |
AF Gazdar, JD Minna |
| Deposited As |
Homo sapiens |
| Year of Origin |
1979 |
| References |
NCI-Navy Medical Oncology Branch Cell Line Supplement. J. Cell. Biochem. suppl. 24: 1996.
|
